The effect of resveratrol on pharmacokinetics of aripiprazole in vivo and in vitro

References

• Agarwal B, Baur JA. (2011). Resveratrol and life extension. Ann NY Acad Sci 1215:138–43
   PubMed Web of Science ®Google Scholar
• Ambavaram VB, Nandigam V, Vemula M, et al. (2013). Liquid chromatography–tandem mass spectrometry method for simultaneous quantification of urapidil and aripiprazole in human plasma and its application to human pharmacokinetic study. Biomed Chromatogr 27:916–23
   PubMed Web of Science ®Google Scholar
• Azuma J, Hasunuma T, Kubo M, et al. (2012). The relationship between clinical pharmacokinetics of aripiprazole and CYP2D6 genetic polymorphism: effects of CYP enzyme inhibition by coadministration of paroxetine or fluvoxamine. Eur J Clin Pharmacol 68:29–37
   PubMed Web of Science ®Google Scholar
• Baur JA, Pearson KJ, Price NL, et al. (2006). Resveratrol improves health and survival of mice on a high-calorie diet. Nature 444:337–42
   PubMed Web of Science ®Google Scholar
• Baur JA, Sinclair DA. (2006). Therapeutic potential of resveratrol: the in vivo evidence. Nat Rev Drug Discov 5:493–506
   PubMed Web of Science ®Google Scholar
• Bradamante S, Barenghi L, Villa A. (2004). Cardiovascular protective effects of resveratrol. Cardiovasc Drug Rev 22:169–88
   PubMed Web of Science ®Google Scholar
• Caloro M, Lionetto L, Cuomo I, et al. (2012). An improved simple LC-MS/MS method for the measurement of serum aripiprazole and its major metabolite. J Pharm Biomed Anal 62:135–9
   PubMed Web of Science ®Google Scholar
• Dai DP, Wang YH, Wang SH, et al. (2013). In vitro functional characterization of 37 CYP2C9 allelic isoforms found in Chinese Han population. Acta Pharmacol Sin 34:1449–56
   PubMed Web of Science ®Google Scholar
• Huber K, Superti-Furga G. (2011). After the grape rush: sirtuins as epigenetic drug targets in neurodegenerative disorders. Bioorg Med Chem 19:3616–24
   PubMed Web of Science ®Google Scholar
• Kirschbaum KM, Muller MJ, Malevani J, et al. (2008). Serum levels of aripiprazole and dehydroaripiprazole, clinical response and side effects. World J Biol Psychiatry 9:212–18
   PubMed Web of Science ®Google Scholar
• Lancon A, Kaminski J, Tili E, et al. (2012). Control of MicroRNA expression as a new way for resveratrol to deliver its beneficial effects. J Agric Food Chem 60:8783–9
   PubMed Web of Science ®Google Scholar
• Li H, Yan Z, Zhu J, et al. (2011). Neuroprotective effects of resveratrol on ischemic injury mediated by improving brain energy metabolism and alleviating oxidative stress in rats. Neuropharmacology 60:252–8
   PubMed Web of Science ®Google Scholar
• Liang F, Terry AV, Bartlett MG. (2012). Determination of aripiprazole in rat plasma and brain using ultra-performance liquid chromatography/electrospray ionization tandem mass spectrometry. Biomed Chromatogr 26:1325–32
   PubMed Web of Science ®Google Scholar
• Liu XY, Xu T, Li WS, et al. (2013). The effect of apigenin on pharmacokinetics of imatinib and its metabolite N-desmethyl imatinib in rats. BioMed Res Int 2013:789184
   PubMedGoogle Scholar
• Mei YZ, Liu RX, Wang DP, et al. (2015). Biocatalysis and biotransformation of resveratrol in microorganisms. Biotechnol Lett 37:9–18
   PubMed Web of Science ®Google Scholar
• Nagai G, Mihara K, Nakamura A, et al. (2012). Prolactin concentrations during aripiprazole treatment in relation to sex, plasma drugs concentrations and genetic polymorphisms of dopamine D2 receptor and cytochrome P450 2D6 in Japanese patients with schizophrenia. Psychiatry Clin Neurosci 66:518–24
   PubMed Web of Science ®Google Scholar
• Okawara M, Katsuki H, Kurimoto E, et al. (2007). Resveratrol protects dopaminergic neurons in midbrain slice culture from multiple insults. Biochem Pharmacol 73:550–60
   PubMed Web of Science ®Google Scholar
• Opie LH, Lecour S. (2007). The red wine hypothesis: from concepts to protective signalling molecules. Eur Heart J 28:1683–93
   PubMed Web of Science ®Google Scholar
• Shapiro DA, Renock S, Arrington E, et al. (2003). Aripiprazole, a novel atypical antipsychotic drug with a unique and robust pharmacology. Neuropsychopharmacology 28:1400–11
   PubMed Web of Science ®Google Scholar
• Shi R, Li W, Liu G, et al. (2013). Catalytic mechanism of cytochrome P450 2D6 for 4-hydroxylation of aripiprazole: a QM/MM study. Chin J Chem 31:1219–27
   Web of Science ®Google Scholar
• Simao F, Matte A, Matte C, et al. (2011). Resveratrol prevents oxidative stress and inhibition of Na(+)K(+)-ATPase activity induced by transient global cerebral ischemia in rats. J Nutr Biochem 22:921–8
   PubMed Web of Science ®Google Scholar
• Swainston Harrison T, Perry CM. (2004). Aripiprazole: a review of its use in schizophrenia and schizoaffective disorder. Drugs 64:1715–36
   PubMed Web of Science ®Google Scholar
• Wang L, Wang Z, Xia MM, et al. (2014a). Inhibitory effect of silybin on pharmacokinetics of imatinib in vivo and in vitro. Can J Physiol Pharmacol 92:961–4
   PubMed Web of Science ®Google Scholar
• Wang Z, Sun W, Huang CK, et al. (2014b). Inhibitory effects of curcumin on activity of cytochrome P450 2C9 enzyme in human and 2C11 in rat liver microsomes. Drug Dev Ind Pharm 41:613–16
   PubMed Web of Science ®Google Scholar
• Wang Y, Jiang Y, Fan X, et al. (2015). Hepato-protective effect of resveratrol against acetaminophen-induced liver injury is associated with inhibition of CYP-mediated bioactivation and regulation of SIRT1-p53 signaling pathways. Toxicol Lett 236:82–9
   PubMed Web of Science ®Google Scholar
• Whitlock NC, Baek SJ. (2012). The anticancer effects of resveratrol: modulation of transcription factors. Nutr Cancer 64:493–502
   PubMed Web of Science ®Google Scholar
• Wu JM, Hsieh TC. (2011). Resveratrol: a cardioprotective substance. Ann NY Acad Sci 1215:16–21
   PubMed Web of Science ®Google Scholar
• Zhang F, Liu J, Shi JS. (2010). Anti-inflammatory activities of resveratrol in the brain: role of resveratrol in microglial activation. Eur J Pharmacol 636:1–7
   PubMed Web of Science ®Google Scholar